67 results about "Memory disorder" patented technology

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention belongs to the technical field of marine biological medicines, and relates to a hippocampus polypeptide for improving cognitive impairment of Alzheimer's disease and a preparation method and application thereof.The preparation method comprises the steps that hippocampus powder is dissolved in water, the pH value is adjusted to 1.8-2.5, pepsin is added for oscillation incubation for 2 hours, and then high-temperature heating is conducted to inactivate enzyme; adjusting the pH value to 7.3-8.0, adding chymotrypsin to form a compound enzyme enzymolysis combination, oscillating and incubating for 2 hours, and heating at high temperature to inactivate the enzyme; centrifuging the solution, collecting enzymatic hydrolysate, and filtering the obtained hippocampus crude polypeptide through an ultrafiltration membrane to obtain molecular weight lt; the hippocampus polypeptide is subjected to vacuum freeze drying and preservation. The hippocampus polypeptide extracted and prepared from hippocampus japonicus by adopting a biological enzymolysis method has excellent APP inhibitory activity, can remarkably improve dysmnesia, and can be used for developing related functional foods or medicines for treating Alzheimer's disease.

The present invention relates to a pharmaceutical composition for the prevention or treatment of degenerative brain diseases, comprising selexipag or a pharmaceutically acceptable salt thereof as an active ingredient. Selexipag inhibits the expression and production of pro-inflammatory or inflammatory cytokines in brain tissue, inhibits the activity of microglia or astrocytes, inhibits NLRP3 inflammasome activity and CDK6 expression, reduces amyloid plaques, increases the expression of the amyloid beta-degrading enzyme IDE, and inhibits the hyperphosphorylation of tau protein and the expression of tau kinase, and thus can be effectively used as a novel therapeutic agent for the prevention or treatment of degenerative brain diseases, cognitive disorders, learning disabilities, or memory disorders.

Methods are provided for determining a memory impairment probability. The method comprises receiving one or more audio recordings of an interaction by a user with a computing device during an assessment; extracting acoustic and speech timing features from the one or more audio recordings; applying a machine learning model to the acoustic and speech timing features to generate a memory impairment probability for the user; and providing a clinical decision support recommendation for a provider based on the memory impairment probability.

The present invention provides a method of treating Parkinson's disease by light stimulation in which light of a specific wavelength such as violet light is irradiated at a specific blinking frequency. The present invention, by irradiating light of a specific wavelength such as violet light to a living body, carries out treatment and / or prophylaxis of Parkinson's disease by improving or suppressing at least one symptom selected from a group of symptoms consisting of cognitive memory disorder, working memory disorder, dysphoria, anxiety, apathy, psychological symptoms (hallucination, visual hallucination, and auditory hallucination), impulse control disorder, orthostatic hypotension, urinary disorder, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorder, pain, weight loss, olfactory abnormality, fatigue, and diaphoresis.

The invention discloses a traditional Chinese medicine composition for alleviating brain degenerative diseases as well as a preparation method and application thereof, and belongs to the technical field of medicines. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 15 to 20 parts of radix polygoni multiflori preparata, 15 to 20 parts of herba cistanche, 10 to 20 parts of fructus corni, 10 to 18 parts of rhizoma chuanxiong, 15 to 22 parts of radix polygalae, 10 to 20 parts of rhizoma acori graminei, 2 to 6 parts of leech, 15 to 22 parts of radix salviae miltiorrhizae and 2 to 6 parts of rhizoma zingiberis recens. The added components have the effects of tonifying the kidney, promoting blood circulation, removing blood stasis, eliminating phlegm, inducing resuscitation, dredging collaterals and the like together, can relieve symptoms such as memory impairment, cognitive impairment, dull expressions, undesirable speech, insatisfactory words, soreness and weakness of the waist, poor appetite, anorexia, poor breath, laziness to speak and the like, and have the effects of improving memory, improving cognitive function, regulating emotion and the like.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

To provide an expression construct for a protein for enhancing spines that can be introduced into neurons to increase a spine volume.SOLUTION: Provided are: [1] an expression construct for a protein for enhancing spines including a promoter for expression that functions in nerve cells, a domain of a Kalirin-7 protein required for at least spine enhancement, operably linked to the promoter, and a nucleotide sequence encoding a protein J1 that forms a heterodimer in the presence of a dimer-inducing compound; and [2] an expression construct for a protein for enhancing spines including a promoter for expression that functions in nerve cells, a domain of a PSD-95 protein required for the localization to at least a postsynaptic membrane, operably linked to the promoter, and a nucleotide sequence encoding a protein J2 that forms a heterodimer in the presence of a dimer-inducing compound.SELECTED DRAWING: None

The subject of the invention is an application of white birch liquid for improving memory. The invention discloses an application of a betula platyphylla sap extract in preparation of a medicine or a health food, wherein the medicine or the health food is beneficial to improving memory disorder. The invention further discloses a preparation method of the betula platyphylla sap extract, and an application of the betula platyphylla sap extract in preparation of the medicine or the health food. The white birch extract related product disclosed by the invention has the characteristics of high efficiency, safety and convenience, and can be used for effectively treating, preventing or slowing down the dysmnesia in manners of medicines, diet intervention or nutritional health-care products and the like. The invention also provides methods of treating, preventing or slowing memory disorders using the betula platyphylla extract.

The present invention relates to a use of a methylated peptide as a therapeutic agent for degenerative brain diseases. Specifically, it has been confirmed that the methylated peptide according to the present invention exhibits improved solubility, bioavailability, phagocytosis by microglia, and anti-inflammatory efficacy compared to a conventional unmodified peptide, and exhibits excellent amyloid beta reduction efficacy compared to a conventional unmodified peptide in an animal model of degenerative brain diseases. Therefore, the methylated peptide according to the present invention can be usefully used as an active ingredient of a composition for preventing or treating degenerative brain diseases and cognitive impairment, learning disability, or memory impairment associated therewith.

The present invention relates to a salidroside derivative, specifically a hydroxy-α-salidroside compound. The hydroxy-α-salidroside compound is superior to α-salidroside in scavenging DPPH free radicals, whitening skin, and improving learning and memory disorders. The compound can be added as a new functional ingredient to cosmetics, functional foods, or pharmaceutical compositions. The preparation method of the hydroxy-α-salidroside of the present invention uses α-salidroside as a substrate and synthesizes hydroxy-α-salidroside under the action of hydroxylase.

The invention provides an electroencephalogram signal-based dysmnesia assessment system, which comprises a signal acquisition module for acquiring an electroencephalogram signal of a target object; the preprocessing module is used for performing 0.5-40Hz band-pass filtering on the electroencephalogram signal of the target object; the signal segmentation module is used for segmenting each channel and determining a plurality of non-overlapping Epoches corresponding to each channel; the feature extraction module is used for performing linear feature extraction and nonlinear feature extraction on each Epoch in each channel, and determining electroencephalogram signal fusion features of the target object based on the linear feature and the nonlinear feature of each Epoch; and the dysmnesia assessment module is used for inputting the electroencephalogram signal fusion features into a trained dysmnesia assessment model, and performing dysmnesia assessment on the target object by using the dysmnesia assessment model to obtain a dysmnesia assessment result of the target object. According to the scheme, dysmnesia evaluation of the target object can be efficiently realized.

Disclosed are methods for assessing severity, determining future risk, matching with a drug treatment, and measuring response to treatment, for memory dysfunction, Alzheimer's disease, and cognitive decline. Also disclosed are new methods of use for drugs and natural compounds repurposed for use in improving memory, as well as for preventing and treating memory disorders, Alzheimer's disease and cognitive decline. All the above-mentioned methods are computer assisted methods analyzing the expression of panels of genes, clinical measures, and drug databases. A universal approach in everybody, as well as a personalized approaches by gender, and by diagnosis, are disclosed.

The invention discloses an application of mitochondrial topoisomerase I or a coding gene thereof, relates to the technical field of biological medicines, and particularly provides an application of the mitochondrial topoisomerase I or the coding gene thereof as a therapeutic target in screening or preparing a medicine for treating Alzheimer's disease. The action mechanism of the mitochondrial topoisomerase I in the Alzheimer's disease is fully explored, it is found that deletion of the coding gene of the mitochondrial topoisomerase I can cause increase of APP and A beta levels and finally cause learning and memory impairment similar to the Alzheimer's disease, and the mitochondrial topoisomerase I can be used as a potential target for treatment of the Alzheimer's disease and can be used for treating the Alzheimer's disease. The overexpressed mitochondrial topoisomerase I can significantly reduce APP and A beta levels and treat the Alzheimer's disease.

Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI). vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption / bioavailability.

The invention discloses application of Cacumen biotae-derived extracellular vesicles in preparation of drugs for treating anxiety, depression or insomnia. The EVs are separated and purified from cacumen biotae through a specific differential ultracentrifugation method, the EVs have a typical double-layer membrane structure, the average particle size is about 100 nm, about 1012 EVs can be extracted from each gram of cacumen biotae, and 62 volatile components are contained. Cacumen biotae EVs can be taken by PC12 cells, and corticosterone-induced neuron damage can be relieved; for chronic constraint stress model mice, anxiety behaviors and spatial learning and memory disorders can be improved, and central nervous inflammation can be inhibited; for chronic unpredictable mild stress model mice, the weight, the sucrose preference rate and the cognitive ability can be recovered, and the levels of 5-hydroxytryptamine and gamma-aminobutyric acid are increased; and for 4-chloro-DL-phenylalanine induced insomnia model mice, the sleep condition can be improved, the neurotransmitter level can be recovered, and the effect is equivalent to that of positive drugs such as citalopram, fluoxetine, diazepam and the like.

The present invention provides a Chinese medicine composition for treating or preventing Alzheimer's disease, and its preparation method and application, wherein the Chinese medicine composition comprises the following raw materials in parts by mass: 10-20 parts of ginseng, 10-20 parts of polygala, 10-20 parts of calamus, 10-20 parts of tuckahoe, 10-20 parts of yam, 10-20 parts of polygonatum, 10-20 parts of green tea pigments and 10-20 parts of quercetin, and optionally comprises 0.1-0.5 parts of black pepper. The Chinese medicine composition of the present invention has a significant therapeutic effect on 5XFAD transgenic AD mice, which is specifically manifested in that daily oral administration of the Chinese medicine composition of the present invention improves the spatial learning and memory disorders of dementia mice, reduces the deposition of amyloid plaques in the dentate gyrus of the hippocampus of mice, and significantly inhibits the generation of Aβ without causing liver and kidney toxicity and weight loss. Therefore, the Chinese medicine composition of the present invention is a safe and effective method for treating AD.

1. Name of the Design Product: Dynamic Graphical User Interface for Neurorehabilitation Training of Display Screen Panel. 2. Use of the Design Product: Used for displaying graphical user interface and interaction. 3. Design Key Points of the Design Product: Lie in the interface content of the graphical user interface on the screen. 4. Picture or Photo that Best Illustrates the Design Key Points: Front View. 5. The display screen panel is of conventional design, so the left view, right view, top view, bottom view are omitted; the rear view is omitted. 6. Use of the Graphical User Interface: Used for the rehabilitation training of patients with memory disorders. 7. Human-Machine Interaction Method of the Graphical User Interface: Clicking, voice prompts, and blood oxygen data of the trainee. 8. Explanation of the Changing States of the Graphical User Interface: The front view is the welcome interface for neurorehabilitation training, with a voice prompt "Training items are being loaded, please wait a moment" and enters the interface changing state diagram 1, which is the training item loading interface; the interface changing state diagram 2 is the interface when the item loading is about to be completed; the interface changing state diagram 3 is the resting state interface during the training process of the trainee after the loading of the item is completed; the interface changing state diagram 4 is the interface ending the resting state stage, and a voice prompt: "Please try to remember the colored graphics that appear on the carriage" is given, and at the same time as the voice prompt, it enters the interface changing state diagram 5; the interface changing state diagram 5 is the teaching training stage interface during the training process of the trainee, the interface changing state diagram 6 is the animation interface at the end of the teaching training stage of the trainee; the interface changing state diagram 7 is the animation interface at the end of the teaching training stage of the trainee; from the interface changing state diagram 3 to the interface changing state diagram 4 is the resting state stage during the training process; from the interface changing state diagram 5 to the interface changing state diagram 7 is the teaching training stage during the training process, and while testing from the interface changing state diagram 3 to the interface changing state diagram 7, the blood oxygen concentration of the trainee is determined and then enters the interface changing state diagram 8, which is the interface showing the start screen of the training; the interface changing state diagrams 9-13 are the interfaces of the training questions; in the interface changing state diagrams 9 to 13, the vines on the roof of the carriage become longer or shorter according to the blood oxygen concentration of the trainee; the interface changing state diagram 13 is the last question, and after the end, it enters the interface changing state diagram 14, and at the same time a voice prompt: "Training ended". 9. Other Situations Requiring Explanation: Other Explanation: The display screen panel and the displayed graphical user interface are applied to computers, laptops, tablets, and mobile phones. The blood oxygen concentration data is received through a communication connection in the near-infrared data acquisition module.

The invention discloses a proteolysis targeting chimeric molecule capable of degrading PTBP1 in a targeting manner as well as a preparation method and application of the proteolysis targeting chimeric molecule. The invention relates to a protease targeted chimeric RNA-PTAC of a nucleic acid ligand. The protease targeted chimeric RNA-PTAC is formed by connecting an E3 ubiquitin ligase ligand pomalidomide and an RNA fragment capable of being specifically combined with PTBP1 protein through polyethylene glycol Linker. The invention relates to an RNA-PROTAC (Ribonucleic Acid-PROTAC) brain targeting delivery preparation, which is a complex obtained by coupling cell penetrating peptides TAT and RVG (Recombinant Virus Growth) with the RNA-PROTAC. According to the TR + RNA-PROTAC complex disclosed by the invention, the targets of efficiently degrading PTBP1 protein in vitro and degrading PTBP1 protein in a brain in a targeted manner in vivo are achieved through the complex, and in-vivo experiments also prove that the TR + RNA-PROTAC complex can be used for treating learning and memory disorders of mice caused by A beta and shows a good curative effect of resisting Alzheimer's disease.

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The invention discloses bifidobacterium pseudolongum LCPJ07 and application thereof in production of sialic acid and improvement of senescence or diabetes related cognitive impairment, and belongs to the technical field of functional microorganisms. The strain can be used for improving cognitive and memory impairment of mice with Alzheimer's disease, and the strain or a preparation containing the strain can enrich sialic acid, improve behavior change of the mice with cognitive impairment induced by senescence or diabetes, regulate brain region inflammation unbalance of the mice with cognitive impairment, effectively remodel the structure of intestinal flora of the mice with cognitive impairment and improve the immunity of the mice with cognitive impairment. The relative abundance of intestinal beneficial bacteria is improved. The bifidobacterium pseudolongum LCPJ07 disclosed by the invention can be used for preparing diets or medicines for preventing or treating different types of cognitive impairments, and has a very wide application prospect.

The invention discloses application of a Lactobacillus johnsonii composite bacterial agent in preparing a drug for preventing and treating memory impairment caused by plateau hypoxia, and belongs to the field of microorganisms. The composite bacterial agent of Lactobacillus johnsonii YH1136 and Bacillus subtilis BS01 provided by the invention can effectively prevent and treat brain memory dysfunction caused by exposure to a plateau hypoxic environment. The composition can restore spatial memory ability, significantly reduce the escape latency, significantly increase the expression level of hippocampal memory-related proteins, significantly increase the antioxidant capacity of the hippocampus in the brain, and alleviate oxidative damage to the hippocampus. The composite bacterial agent of Lactobacillus johnsonii YH1136 and Bacillus subtilis BS01 provided by the invention can be used to prepare a drug for preventing and treating brain memory dysfunction caused by exposure to a plateau hypoxic environment and a composition thereof, and can also be used as an auxiliary product of existing therapeutic drugs and treatment methods, and has very broad application prospects.

The invention discloses application of TRPM8 in preparation of a medicine for preventing and / or treating learning and memory disorder related diseases. The application provides a new treatment target or strategy for learning and memory disorder related diseases.

The present invention aims to provide a method for evaluating dementia and a composition for preventing or treating deterioration in brain function, or for maintaining or improving brain function, and compared the gut microbiota of healthy individuals, individuals with mild cognitive impairment, and individuals with Alzheimer's disease. As a result, gut microorganisms were selected, such as microorganisms belonging to the genus Faecalibacterium, that are associated with cognitive function. Furthermore it was revealed that Faecalibacterium prausnitzii, possessing specific DNA, exhibited an improvement effect against brain function deterioration, such as learning and memory disorders.

To deal with dementia of elderly people or difficulties of communications due to memory disorder.SOLUTION: A communication assist system includes: means for a family and an elderly person to wear a virtual reality goggle and regenerate images in the past; means for the family and the elderly person to have a conversation through an artificial intelligence chat bot; and means for digitizing the conversation and experiencing the conversation in combination with pictures of the elderly person.SELECTED DRAWING: Figure 1

The present invention relates to a composition for the prevention, improvement, or treatment of memory impairment or cognitive impairment comprising a black pepper (Piper nigrum) extract, and more specifically, to a composition for the prevention, improvement, or treatment of memory impairment or cognitive impairment induced by scopolamine comprising a black pepper 70% (v / v) ethanol extract as an active ingredient. It was confirmed that the black pepper extract of the present invention, particularly the black pepper ethanol extract, contains a high content of piperine and effectively inhibits the inflammatory response induced in LPS-stimulated microglia without cytotoxicity compared to Indian pepper (Piper longum) or black pepper methanol extract. Furthermore, the black pepper extract of the present invention showed memory-enhancing effects in the Y-maze test and passive avoidance test using mice with memory impairment induced by scopolamine, and since the BDNF-CREB pathway activation effect was confirmed, it can be usefully utilized as a composition for the prevention, improvement, or treatment of memory impairment or cognitive impairment induced by scopolamine.

The present invention provides a method of treating Parkinson's disease by light stimulation in which light of a specific wavelength such as violet light is irradiated at a specific blinking frequency. The present invention, by irradiating light of a specific wavelength such as violet light to a living body, carries out treatment and / or prophylaxis of Parkinson's disease by improving or suppressing at least one symptom selected from a group of symptoms consisting of cognitive memory disorder, working memory disorder, dysphoria, anxiety, apathy, psychological symptoms (hallucination, visual hallucination, and auditory hallucination), impulse control disorder, orthostatic hypotension, urinary disorder, sexual dysfunction, digestive symptoms (drooling, swallowing, nausea, constipation), sleep disorder, pain, weight loss, olfactory abnormality, fatigue, and diaphoresis.

The invention provides a lactobacillus paracasei and breast milk oligosaccharide composition capable of synergistically preventing and treating Alzheimer's disease, the active ingredients of the composition comprise lactobacillus paracasei L9 and breast milk oligosaccharide, the L9 strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the classification name is lactobacillus paracasei, the preservation number is CGMCC No.9800, the preservation number is CGMCC No.9800, the preservation number is CGMCC No.9800, and the preservation number is CGMCC No.9800. The preservation date is October 22, 2014. In the composition disclosed by the invention, the lactobacillus paracasei and the breast milk oligosaccharide have potential interaction, can cooperate with each other and can play a synergistic role, and reference indexes are provided for industrial production of the probiotic and prebiotic compound composition by improving spatial learning and memory disorder, synaptic plasticity disorder and neuroinflammation. And theoretical basis and data support are provided for popularization and application of the probiotic and prebiotic compound composition in the field of prevention and treatment of Alzheimer's disease.

The invention provides a medicine for treating learning and memory impairment of Alzheimer's disease and application. The medicine at least comprises PF-4708671, and the medicine at least comprises The learning and memory ability is tested and evaluated by using two AD mice as models, a 5xFAD transgenic mouse can simulate the advanced neuropathological process and behavioral performance of an AD patient in the early stage, and an A [beta] O injection mouse model not only can simulate abnormal behaviors of AD diseases, but also can simulate the advanced neuropathological process and behavioral performance of the AD patient in the later stage. A beta O is injected into a mouse model, and an injection brain region is selected to control ABO to intervene in a specific brain region, so that PF-4708671 can penetrate through a blood brain barrier to reach a target disease site, a new treatment direction is provided for AD (Alzheimer's disease), and particularly, a new drug selection is provided for learning and memory disorder caused by the Alzheimer's disease.

The present invention provides a novel memory disorder ameliorating agent. A PKC [gamma] activity inhibitor is useful as an active ingredient of a dysmnesia ameliorating agent.